[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evolus Inc (EOLS)

Evolus Inc (EOLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Evolus to Participate in The Jefferies Global Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in...

EOLS : 6.90 (+2.37%)
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme ...

EOLS : 6.90 (+2.37%)
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook

Global Net Revenue of $73.1 Million for the First Quarter of 2026, Up 7% Over the Prior Year and Against the Highest Growth Quarter of 2025 GAAP Operating...

EOLS : 6.90 (+2.37%)
Can Evolus Convince Anyone the Jeuveau Slowdown Is Already Over?

Barchart Research What to Expect from EOLS Earnings EOLS Generated May 1, 2026 Current Price $5.33 EPS Estimate $$-0.22 Consensus Rating Moderate Buy Average Move 14.25% Can Evolus Convince Anyone the...

EOLS : 6.90 (+2.37%)
Can Evolus Convince Anyone the Jeuveau Slowdown Is Already Over?

Barchart Research What to Expect from EOLS Earnings EOLS Generated May 1, 2026 Current Price $5.33 EPS Estimate $$-0.22 Consensus Rating Moderate Buy Average Move 14.25% Can Evolus Convince Anyone the...

EOLS : 6.90 (+2.37%)
Can Evolus Convince Anyone the Jeuveau Slowdown Is Already Over?

Barchart Research What to Expect from EOLS Earnings EOLS Generated May 1, 2026 Current Price $5.33 EPS Estimate $$-0.22 Consensus Rating Moderate Buy Average Move 14.25% Can Evolus Convince Anyone the...

EOLS : 6.90 (+2.37%)
Evolus to Report First Quarter Financial Results on May 4, 2026

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial...

EOLS : 6.90 (+2.37%)
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in...

EOLS : 6.90 (+2.37%)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Evolus, Inc. (NASDAQ: EOLS) a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during March 2026 of an aggregate of 85,516 restricted...

EOLS : 6.90 (+2.37%)
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026

Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year ...

EOLS : 6.90 (+2.37%)

Barchart Exclusives

FedEx Is Abandoning Its Supply Chain Business. FDX Stock Investors Need the Logistics Giant to Protect Its Core Network.
FedEx is selling FedEx Supply Chain to shipping giant CMA CGM for $1.4 billion, narrowing its focus to premium B2B shipping, logistics, and freight moves. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.